Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Angiodynamics (ANGO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to 7.71%.

  • Angiodynamics' EBITDA Margin rose 75200.0% to 7.71% in Q4 2025 from the same period last year, while for Nov 2025 it was 10.59%, marking a year-over-year increase of 726700.0%. This contributed to the annual value of 13.66% for FY2025, which is 496600.0% up from last year.
  • According to the latest figures from Q4 2025, Angiodynamics' EBITDA Margin is 7.71%, which was up 75200.0% from 14.07% recorded in Q3 2025.
  • Over the past 5 years, Angiodynamics' EBITDA Margin peaked at 44.52% during Q3 2023, and registered a low of 265.88% during Q1 2024.
  • In the last 5 years, Angiodynamics' EBITDA Margin had a median value of 12.47% in 2021 and averaged 23.25%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -2548200bps in 2024, then surged by 2520300bps in 2025.
  • Quarter analysis of 5 years shows Angiodynamics' EBITDA Margin stood at 11.09% in 2021, then rose by 14bps to 9.5% in 2022, then crashed by -75bps to 16.59% in 2023, then increased by 8bps to 15.23% in 2024, then soared by 49bps to 7.71% in 2025.
  • Its EBITDA Margin was 7.71% in Q4 2025, compared to 14.07% in Q3 2025 and 7.22% in Q2 2025.